Modulation of macrophage phenotype by soluble product(s) released from neutrophils.
The regulation of macrophage phenotype by neutrophils was studied in the s.c. polyvinyl alcohol sponge wound model in mice made neutropenic by anti-Gr-1 Ab, as well as in cell culture. Wounds in neutropenic mice contained 100-fold fewer neutrophils than those in nonneutropenic controls 1 day after sponge implantation. Wound fluids from neutropenic mice contained 68% more TNF-alpha, 168% more IL-6, and 61% less TGF-beta1 than those from controls. Wound fluid IL-10 was not different between the two groups, and IL-4 was not detected. Intracellular TNF-alpha staining was greater in cells isolated from neutropenic wounds than in those from control wounds. The hypothesis that wound neutrophil products modulate macrophage phenotype was tested in Transwell cocultures of LPS-stimulated J774A.1 macrophages and day 1 wound cells (84% neutrophils/15% macrophages). Overnight cocultures accumulated 60% less TNF-alpha and IL-6 than cultures of J774A.1 alone. The suppression of cytokine release was mediated by a soluble factor(s), because culture supernatants from wound cells inhibited TNF-alpha and IL-6 release from LPS-stimulated J774A.1 cells. Culture supernatants from purified wound neutrophils equally suppressed TNF-alpha release from LPS-stimulated J774A.1 cells. Wound cell supernatants also suppressed TNF-alpha and superoxide release from murine peritoneal macrophages. The TNF-alpha inhibitory factor has a molecular mass <3000 Da and is neither PGE2 nor adenosine. The present findings confirm a role for neutrophils in the regulation of innate immune responses through modulation of macrophage phenotype.
Daley
Jean M
JM
Department of Surgery, Division of Surgical Research, Rhode Island Hospital and Brown Medical School, Providence, RI 02903, USA. jdaley@lifespan.org
Reichner
Jonathan S
JS
Mahoney
Eric J
EJ
Manfield
Laura
L
Henry
William L
WL
Mastrofrancesco
Balduino
B
Albina
Jorge E
JE
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000943:Antigens, Differentiation / Q000276:immunology; D001684:Biological Dressings; D002460:Cell Line; D002465:Cell Movement / Q000276:immunology; D002474:Cell-Free System / Q000276:immunology; D018920:Coculture Techniques; D017077:Culture Media, Conditioned / Q000378:metabolism; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D016130:Immunophenotyping; D018836:Inflammation Mediators / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D017737:Macrophages, Peritoneal / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009503:Neutropenia / Q000276:immunology; D009504:Neutrophils / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D011142:Polyvinyl Alcohol; D012995:Solubility; D013481:Superoxides / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism; D014945:Wound Healing / Q000276:immunology; D014949:Wounds, Nonpenetrating / Q000276:immunology / Q000473:pathology; D000093242:Interleukin-6 Inhibitors
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D017077:Culture Media, Conditioned; D016207:Cytokines; D018836:Inflammation Mediators; D015850:Interleukin-6; D008070:Lipopolysaccharides; D011142:Polyvinyl Alcohol; D013481:Superoxides; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors; C046168:neutrophil differentiation antigens